The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025
- 25 October 2025
- journal article
- Published by Wiley in Haemophilia
- Vol. 32 (1) , 20-54
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1Journal of Thrombosis and Haemostasis, 2023
- AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injuryHepatology, 2023
- Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologistsJournal of Thrombosis and Haemostasis, 2023
- Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and cliniciansBlood Reviews, 2022
- Patient selection for hemophilia gene therapy: Real‐life data from a single centerResearch and Practice in Thrombosis and Haemostasis, 2021
- Evidence vs Consensus in Clinical Practice GuidelinesJAMA, 2019
- Adenovirus‐associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus‐associated virus vector–serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia AResearch and Practice in Thrombosis and Haemostasis, 2019
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- Living systematic review: 1. Introduction—the why, what, when, and howJournal of Clinical Epidemiology, 2017
- Living systematic reviews: 4. Living guideline recommendationsJournal of Clinical Epidemiology, 2017